Unigen expands into Europe, Latin America

Related tags European union Europe

Unigen Pharmaceuticals has expanded its sales presence in Europe
and Latin America by signing agency and distribution agreements
with six international corporate partners

Ingredients company Unigen Pharmaceuticals has expanded its sales presence in Europe and Latin America by signing agency and distribution agreements with six international corporate partners. The company is also planning to sign up a distributor in France before the end of this month.

The six European partners are: Lake Chemical in the United Kingdom; CH Erbshloh in Germany, Poland, Austria and Switzerland; Bionord in Denmark, Sweden, Finland and Norway; Pharmalogic in Denmark, Sweden, Finland, Norway, Italy, Greece and Poland; Zeus Quimica in Spain and Portugal; and Will & Co in Belgium and the Netherlands. In addition, Unigen has expanded into the Brazilian market after signing up local firm Ayalla Marketing.

"Many international companies are answering the call for finished products made with novel and efficacious active ingredients that are backed by sound science​," said Derek Hall, Unigen's chief executive. The company, which specialises in the development of ingredients from botanical sources such as ginseng, soy, rice and aloe vera, indicated that its product range would be rolled out by the new distributors rapidly.

Related news

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us

Products

View more

Webinars